Cargando…

Tumor‐derived microparticles in tumor immunology and immunotherapy

Microvesicles or microparticles, a type of cytoplasm membrane‐derived extracellular vesicles, can be released by cancer cells or normal cell types. Alteration of F‐actin cytoskeleton by various signals may lead to the cytoplasm membrane encapsulating cellular contents to form microparticles, which c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Jingwei, Zhang, Huafeng, Tang, Ke, Huang, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Highlights
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702100/ https://www.ncbi.nlm.nih.gov/pubmed/32976623 http://dx.doi.org/10.1002/eji.202048548

Ejemplares similares

Macrophages’ M1 or M2 by tumor microparticles: lysosome makes decision
por: Tang, Ke, et al.
Publicado: (2022)

Macrophages reprogrammed by lung cancer microparticles promote tumor development via release of IL-1β
por: Chen, Jie, et al.
Publicado: (2019)

Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1/PD-L1 immunotherapy
por: Yin, Enzhi, et al.
Publicado: (2023)

Tumor‐derived extracellular vesicles and particles (EVPs): pivotal vectors in driving metabolic reprogramming
por: Su, Xinming, et al.
Publicado: (2023)

Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy
por: Du, Songtao, et al.
Publicado: (2023)

Metabolic interaction: tumor-derived lactate inhibiting CD8(+) T cell cytotoxicity in a novel route
por: Wang, Ke, et al.
Publicado: (2023)

Immunological consequences of strain variation within the Mycobacterium tuberculosis complex
por: Tientcheu, Leopold D., et al.
Publicado: (2017)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Radiotherapy and the tumor microenvironment: The “macro” picture
por: Walton, Emma Louise
Publicado: (2017)

Make immunological peace not war: Potential applications of tolerogenic dendritic cells
por: Walton, Emma Louise
Publicado: (2017)

Measuring single‐cell protein secretion in immunology: Technologies, advances, and applications
por: Bucheli, Olivia T. M., et al.
Publicado: (2021)

Multiomics uncovers developing immunological lineages in human [Image: see text]
por: Stephenson, Emily, et al.
Publicado: (2021)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Innate lymphoid cells and cancer: Role in tumor progression and inhibition
por: Yuan, Xiaodong, et al.
Publicado: (2021)

The thioredoxin system: Balancing redox responses in immune cells and tumors
por: Muri, Jonathan, et al.
Publicado: (2022)

Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response
por: Elliott, Kerryn, et al.
Publicado: (2021)

Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy
por: Nüse, Björn, et al.
Publicado: (2022)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

An effective platform for cancer immunotherapy: pooled knockin targeting for genome engineering
por: Jin, Ke, et al.
Publicado: (2020)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

‘Nur'turing tumor T cell tolerance and exhaustion: novel function for Nuclear Receptor Nur77 in immunity
por: Lith, Sanne C., et al.
Publicado: (2020)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

Circadian‐rhythm‐regulating hormones: Key factors to regulate breast cancer metastasis via circulating tumor cells
por: Liu, Chenguang, et al.
Publicado: (2022)

Pancreatic tumor initiation: the potential role of IL-33
por: Huang, Xing, et al.
Publicado: (2021)

Primer on tumor immunology and cancer immunotherapy
por: Harris, Timothy J, et al.
Publicado: (2013)

Lipid metabolism in tumor immunology and immunotherapy
por: Duong, Lisa K., et al.
Publicado: (2023)

Cancer Environment Immunotherapy: targeting TGF-β finds its way towards tissue healing and vasculature remodeling
por: Jin, Ke, et al.
Publicado: (2021)

Inhibition of tumor autophagy: a strategy to improve anti-tumor immunity?
por: Freeman, Andrew J., et al.
Publicado: (2020)

Histamine in cancer immunology and immunotherapy. Current status and new perspectives
por: Sarasola, María de la Paz, et al.
Publicado: (2021)

Cytotoxic innate lymphoid cells sense tumor-derived IL-15: a novel mechanism of cancer immunosurveillance
por: Franz, Tobias, et al.
Publicado: (2022)

Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody
por: Li, Fang, et al.
Publicado: (2020)

Digitally deconvolving the tumor microenvironment
por: Aran, Dvir, et al.
Publicado: (2016)

ecDNA within tumors: a new mechanism that drives tumor heterogeneity and drug resistance
por: Zeng, Xixi, et al.
Publicado: (2020)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Editorial: New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy
por: Seiffert, Martina, et al.
Publicado: (2022)

Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 2
por: He, Haiyan, et al.
Publicado: (2023)

Irradiated tumor cell–derived microparticles mediate tumor eradication via cell killing and immune reprogramming
por: Wan, Chao, et al.
Publicado: (2020)

Reversing epigenetic repression of transposable elements for improving tumor immunogenicity
por: Wang, Xi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7lnu96sod4gm1fmm49jvhf93ml